News
-
2020-05 29MORE
3D Medicines Announced Clinical Trial Data for Subcutaneous PD-L1 Antibody KN035 Would Be Published on ASCO 2020 Annual Meeting
Beijing, China, May 29, 2020 - 3D Medicines announced that the data from two clinical trials on Envafolimab (KN035) will be published on the 2020 annual meeting of American Society of Clinical Oncology (ASCO).
-
2020-03 30MORE
3D Medicines, Simcere and Alphamab Oncology Announced Partnership to Develop and Commercialize Subcutaneous PD-L1 Antibody for Cancer Indications in Mainland China
Beijing, China, March 30, 2020 – 3D Medicines announced that 3D Medicines (Beijing) Co., Ltd., a wholly-owned subsidiary of 3D Medicines, Inc., has established strategic partnership with Simcere Pharmaceuticals and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. （“Jiangsu Alphamab”）to advance the development and commercialization of Envafolimab (KN035), a checkpoint inhibitor for programmed cell death ligand-1 (PD-L1), for the treatment of cancer indications in mainland China.
-
2020-01 18MORE
PD-L1 Antibody Envafolimab（KN035）Granted Orphan Drug Designation by FDA
January 18, 2020 – 3D Medicines, Inc. (“3D Medicines”）and Alphamab Oncology (stock code: 9966.HK) (“Alphamab”) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PD-L1 antibody KN035 for the treatment of biliary tract cancer (BTC).
-
2019-12 20MORE
3D Medicines, Alphamab and TRACON Reached a Three-way Collaboration to Advance the Clinical Development and Commercialization of KN035, a PD-L1 Single Domain Antibody, in Soft Tissue Sarcoma in North America
December 20, 2019 – 3D Medicines, Inc. (“3D Medicines”) announced that it has signed a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology (Stock code: 9966.HK) and TRACON Pharmaceuticals (“TRACON”) for the clinical development and commercialization of KN035, a PD-L1 single-domain antibody, in soft tissue sarcoma in North America.
-
2019-09 19MORE
3D Medicines Announced Clinical Trial Data for Subcutaneous PD-L1 Antibody KN035 on CSCO 2019 Annual Meeting
On September 19, 2019, 3D Medicines Inc. attended the 22nd annual meeting of Chinese Society of Clinical Oncology (CSCO). Toshio Shimizu, M.D., PhD. from National Cancer Center Hospital, gave an oral presentation on the Clinical Trial Periodic Report of the phase I study for Envafolimab (KN035), a subcutaneous anti-PD-L1 single domain antibody from 3D Medicines, in advanced solid tumor patients in Japan. Details of the presentation are listed as follows:
